Skip to content

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
895.9M-0.5%
Johnson & Johnson logo
Johnson & JohnsonJNJ
2.4B+0.9%
Amgen logo
AmgenAMGN
544M+0.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
107.7M-3.1%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
24.7M+75.9%
Janux Therapeutics logo
Janux TherapeuticsJANX
62.7M+1.4%

Other financials

Income statement

See full
Revenue-
Operating income-$53.7M+2.4%
Net income-$49.7M-2.4%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$75.1M-2.1%
Total debt$2.4M+29.5%
Total equity$408.7M-30.8%
Total assets$403.0M-30.5%

Cash flow

See full
Operating cash flow-$46.0M-6.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.08B+151%
Enterprise value$1.01B+181%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio10.3×-1.3×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed November 7, 2024, on SEC EDGAR. View the filing →

Ask your AI about Cullinan Therapeutics, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cullinan Therapeutics, Inc.'s shares (diluted)?
Cullinan Therapeutics, Inc. (CGEM) reported shares (diluted) of 58.3M in Q3 2024.
How has Cullinan Therapeutics, Inc.'s shares (diluted) changed year-over-year?
Cullinan Therapeutics, Inc.'s shares (diluted) increased by 36.5% year-over-year, from 42.7M to 58.3M.
What is the long-term trend for Cullinan Therapeutics, Inc.'s shares (diluted)?
Over 2 years (2021 to 2023), Cullinan Therapeutics, Inc.'s shares (diluted) has grown at a -2.0% compound annual growth rate (CAGR), from 171.8M to 164.9M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.